Hepatitis Monthly

Published by: Kowsar

A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz

Leila Kasraian 1 , * , Neda Negarestani 2 , Mohammad Hossein Karimi 3 and Sahar Dehbidi 4
Authors Information
1 Associate Professor, Community Medicine Specialist, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Shiraz, IR Iran
2 Assistant Professor, Psychiatrist, Manager of Consultation Center, Iranian Blood Transfusion Research Center, Shiraz, IR Iran
3 PhD of Immunology, Director, President, Iranian Blood Transfusion Research Center, Shiraz Blood Transfusion Organization, Shiraz, IR Iran
4 Master of Cellular and Molecular Science, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: November 01, 2016, 16 (11); e31080
  • Published Online: November 6, 2016
  • Article Type: Research Article
  • Received: December 7, 2015
  • Revised: July 27, 2016
  • Accepted: October 5, 2016
  • DOI: 10.5812/hepatmon.31080

To Cite: Kasraian L, Negarestani N, Karimi M H, Dehbidi S. A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz, Hepat Mon. 2016 ;16(11):e31080. doi: 10.5812/hepatmon.31080.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Alavian SM. Hepatitis C infection in Iran; A review article. Arch Clin Infect Dis. 2009; 4(1): 47-59
  • 2. Martin V, Bernhardsgrutter R, Goebel R, Steinert T. The use of mechanical restraint and seclusion in patients with schizophrenia: a comparison of the practice in Germany and Switzerland. Clin Pract Epidemiol Ment Health. 2007; 3: 1[DOI][PubMed]
  • 3. Barboza KC, Salinas LM, Sahebjam F, Jesudian AB, Weisberg IL, Sigal SH. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis. 2016; 31(4): 869-80[DOI][PubMed]
  • 4. Ersche KD, Fletcher PC, Lewis SJ, Clark L, Stocks-Gee G, London M, et al. Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology (Berl). 2005; 180(4): 612-23[DOI][PubMed]
  • 5. Kiecolt-Glaser JK,, Glaser R. Depression and immune function: central pathways to morbidity and mortality . J Psychosomat Res. 2002; 53(4): 873-6
  • 6. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004; 71 Suppl 3-21[PubMed]
  • 7. Franke L, Therstappen E, Schlosser B, Biermer M, Berg T, Schafer M, et al. A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. Depress Res Treat. 2014; 2014: 821381[DOI][PubMed]
  • 8. Evon DM, Simpson KM, Esserman D, Verma A, Smith S, Fried MW. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther. 2010; 32(9): 1163-73[DOI][PubMed]
  • 9. Carta MG, Hardoy MC. Why a new online open access journal in the field of clinical and epidemiological research in mental health? Clin Pract Epidemiol Ment Health. 2005; 1(1): 1[DOI][PubMed]
  • 10. Alipour A, Nouri N. A study on reliability and validity of the depression-happiness scale in justice's staff of isfahan city. Q J Fundament Ment Health.
  • 11. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003; 44(2): 104-12[PubMed]
  • 12. Grothe KB, Dutton GR, Jones GN, Bodenlos J, Ancona M, Brantley PJ. Validation of the Beck Depression Inventory-II in a low-income African American sample of medical outpatients. Psychol Assess. 2005; 17(1): 110-4[DOI][PubMed]
  • 13. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000; 49(5): 311-7[PubMed]
  • 14. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry. 2005; 27(6): 431-8[DOI][PubMed]
  • 15. Malhotra S, Kaur N, Kumar P, Bhatia M, Hans C. Hepatitis C and Depression. Delhi Psychiatr J. 2011; 14(1): 143-8
  • 16. Harris M. Injecting, infection, illness: abjection and hepatitis C stigma. Body Soc. 2009; 15(4): 33-51
  • 17. Weissenborn K, Tryc AB, Heeren M, Worthmann H, Pflugrad H, Berding G, et al. Hepatitis C virus infection and the brain. Metab Brain Dis. 2009; 24(1): 197-210[DOI][PubMed]
  • 18. Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health. 2004; 81(2): 278-90[PubMed]
  • 19. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005; 11(2): 86-94[DOI][PubMed]
  • 20. Loftis JM, Hauser P. Hepatitis C in patients with psychiatric disease and substance abuse: screening strategies and comanagement models of care. Curr Hepat Rep. 2003; 2(3): 93-100
  • 21. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry. 1985; 42(11): 1067-71[PubMed]
  • 22. Vabo IL, Ferreira LE, Pace FH. Depressive Episode Incidence in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin. Arq Gastroenterol. 2016; 53(1): 20-4[DOI][PubMed]
  • 23. Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009; 7(7): 793-9[DOI][PubMed]
  • 24. Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. Gen Hosp Psychiatry. 2015; 37(6): 533-7[DOI][PubMed]
  • 25. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002; 72(3): 237-41[PubMed]
  • 26. Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol. 2013; 2(4): 139-45[DOI][PubMed]
  • 27. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13): 961-6[DOI][PubMed]
  • 28. Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-alpha. Neuropsychiatr Dis Treat. 2011; 7: 275-92[DOI][PubMed]
  • 29. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry. 2009; 54(9): 614-25[PubMed]
  • 30. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009; 104(12): 2949-58[DOI][PubMed]
  • 31. Pavlovic Z, Delic D, Maric NP, Vukovic O, Jasovic-Gasic M. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub. 2011; 23(4): 370-7[PubMed]
  • 32. Nesic Z, Delic D, Prostran M, Stojanovic R, Vuckovic S, Todorovic Z. [Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C]. Med Pregl. 2004; 57(5-6): 219-26[PubMed]
  • 33. Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008; 27(3): 257-65[DOI][PubMed]
  • 34. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005; 66(1): 41-8[PubMed]
  • 35. Schaefer M, Schmidt F, Neumer R, Scholler G, Schwarz M. Interferon-alpha, cytokines and possible implications for mood disorders. Bipolar Disord. 2002; 4 Suppl 1: 111-3[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments